Evotec SE (EVO) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 22, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2024, filed Apr 17, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the EVO SEC filings page.
Evotec SE (EVO) reported $824.9M in revenue for fiscal year 2024, down 4.6% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Scored against operating companies for FY2024. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Evotec SE's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Evotec SE has an operating margin of -17.9%, meaning the company loses $18 on every $100 of revenue. This results in a profitability score of 17/100. This is down from -6.1% the prior year.
Evotec SE's revenue declined 4.6% year-over-year, from $864.4M to $824.9M. This contraction results in a growth score of 35/100.
Evotec SE carries a low D/E ratio of 0.30, meaning only $0.30 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 69/100, indicating a strong balance sheet with room for future borrowing.
Evotec SE's current ratio of 1.98 indicates adequate short-term liquidity, earning a score of 58/100. The company can meet its near-term obligations, though with limited headroom.
While Evotec SE generated $18.9M in operating cash flow, capex of $121.6M consumed most of it, leaving -$102.7M in free cash flow. This results in a low score of 11/100, reflecting heavy capital investment rather than weak cash generation.
Evotec SE posts a -20.6% return on equity (ROE), meaning it loses $21 for every $100 of shareholders' equity. This results in a returns score of 21/100. This is down from -7.5% the prior year.
Evotec SE scores 0.22, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $696.0M against total assets of $2.0B. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Evotec SE passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.
Evotec SE reported a net loss of $203.0M while generating $18.9M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Evotec SE reported an operating loss of $147.5M against $4.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Evotec SE generated $824.9M in revenue in fiscal year 2024. This represents a decrease of 4.6% from the prior year.
Evotec SE's EBITDA was -$42.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 184.2% from the prior year.
Evotec SE reported a net loss of $203.0M in fiscal year 2024. The change from the prior year is not meaningful, because that figure was zero or negative.
Evotec SE earned -$1.15 per diluted share (EPS) in fiscal year 2024. The change from the prior year is not meaningful, because that figure was zero or negative.
Cash & Balance Sheet
Evotec SE recorded an outflow of $102.7M in free cash flow in fiscal year 2024, representing a cash shortfall after capex. The change from the prior year is not meaningful, because that figure was zero or negative.
Evotec SE held $317.1M in cash against $297.6M in long-term debt as of fiscal year 2024.
Not reported for fiscal year 2024.
Margins & Returns
Evotec SE's gross margin was 14.4% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 8.0 percentage points from the prior year.
Evotec SE's operating margin was -17.9% in fiscal year 2024, reflecting core business profitability. This is down 11.8 percentage points from the prior year.
Evotec SE's net profit margin was -24.6% in fiscal year 2024, showing the share of revenue converted to profit. This is down 13.9 percentage points from the prior year.
Evotec SE's ROE was -20.6% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is down 13.1 percentage points from the prior year.
Capital Allocation
Evotec SE invested $52.6M in research and development in fiscal year 2024. This represents a decrease of 30.6% from the prior year.
Evotec SE invested $121.6M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 48.5% from the prior year.
Not reported for fiscal year 2024.
EVO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F |
|---|---|---|---|---|---|---|
| Revenue | $824.9M-4.6% | $864.4M+7.5% | $803.9M+14.9% | $699.5M+14.2% | $612.6M+22.2% | $501.2M |
| Cost of Revenue | $706.0M+5.3% | $670.8M+8.6% | $617.7M+17.0% | $528.0M+15.1% | $458.8M+30.3% | $352.0M |
| Gross Profit | $118.9M-38.6% | $193.6M+4.0% | $186.2M+8.6% | $171.5M+11.5% | $153.8M+3.1% | $149.2M |
| R&D Expenses | $52.6M-30.6% | $75.8M-7.5% | $82.0M+0.3% | $81.7M+4.5% | $78.2M+19.2% | $65.6M |
| Operating Income | -$147.5Mn/m | -$52.6M-335.6% | $22.3M-51.9% | $46.4M-21.9% | $59.4M-15.6% | $70.4M |
| EBITDA | -$42.3M-184.2% | $50.3M-54.8% | $111.3M-11.7% | $126.1M | N/A | N/A |
| Interest Expense | $4.9M-24.1% | $6.5M-54.1% | $14.1M+34.3% | $10.5M+1.2% | $10.4M+23.7% | $8.4M |
| Income Tax | $2.2M-40.8% | $3.7M-84.2% | $23.2M-4.5% | $24.3M+1.6% | $23.9M+10.1% | $21.7M |
| Net Income | -$203.0Mn/m | -$92.8Mn/m | -$187.9M-177.0% | $243.9M+3076.8% | $7.7M-82.1% | $42.8M |
| EPS (Basic) | -$1.15n/m | -$0.52n/m | -$1.06-172.0% | $1.47+2908.8% | $0.05-82.6% | $0.28 |
| EPS (Diluted) | -$1.15n/m | -$0.52n/m | -$1.06-172.0% | $1.47+2908.8% | $0.05-82.6% | $0.28 |
Not reported in any period shown, so not listed: SG&A Expenses, Diluted Shares (Avg).
EVO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F |
|---|---|---|---|---|---|---|
| Total Assets | $2.0B-20.6% | $2.5B+3.2% | $2.4B-4.5% | $2.5B+41.5% | $1.8B | N/A |
| Current Assets | $705.9M-29.3% | $999.1M-13.0% | $1.1B-7.8% | $1.2B+54.6% | $805.8M | N/A |
| Cash & Equivalents | $317.1M-43.9% | $565.2M+27.3% | $444.1M-43.9% | $791.5M+53.1% | $516.8M+66.2% | $311.0M |
| Inventory | $32.2M-5.7% | $34.2M+7.1% | $31.9M+9.3% | $29.2M+75.7% | $16.6M | N/A |
| Accounts Receivable | $120.4M+10.6% | $108.8M-40.8% | $183.8M | N/A | N/A | N/A |
| Goodwill | $292.8M-4.0% | $304.9M+3.7% | $294.0M+0.9% | $291.5M-3.6% | $302.5M+5.3% | $287.3M |
| Total Liabilities | $993.7M-20.7% | $1.3B+9.4% | $1.1B+18.0% | $970.5M+7.5% | $902.4M | N/A |
| Current Liabilities | $356.7M-30.6% | $513.9M+42.2% | $361.3M-1.6% | $367.3M+44.1% | $254.9M | N/A |
| Non-Current Liabilities | $637.0M-13.8% | $738.9M-5.7% | $783.5M+29.9% | $603.2M-6.8% | $647.5M | N/A |
| Long-Term Debt | $297.6M-38.4% | $483.5M+37.7% | $351.2M-4.9% | $369.4M-8.8% | $404.8M | N/A |
| Total Equity | $986.0M-20.4% | $1.2B-2.5% | $1.3B-18.5% | $1.6B+76.0% | $886.0M+64.9% | $537.3M |
| Retained Earnings | -$696.0Mn/m | -$526.9Mn/m | -$419.8Mn/m | -$244.9Mn/m | -$529.1M | N/A |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments.
EVO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $18.9M-53.2% | $40.3M-81.7% | $220.2M+53.7% | $143.3M+162.0% | $54.7M+15.4% | $47.4M |
| Depreciation & Amortization | $105.2M+2.3% | $102.9M+15.6% | $89.0M+11.7% | $79.7M | N/A | N/A |
| Capital Expenditures | $121.6M-48.5% | $236.0M+21.6% | $194.0M+44.1% | $134.6M+11.1% | $121.2M+244.6% | $35.2M |
| Free Cash Flow | -$102.7Mn/m | -$195.7M-847.8% | $26.2M+201.9% | $8.7Mn/m | -$66.5M-643.5% | $12.2M |
| Investing Cash Flow | -$73.7Mn/m | -$14.7Mn/m | -$441.6Mn/m | -$274.8Mn/m | -$189.7Mn/m | -$97.3M |
| Financing Cash Flow | -$167.1M-309.9% | $79.6Mn/m | -$62.2M-114.0% | $444.8M+47.6% | $301.4M+27.1% | $237.2M |
Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.
EVO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F |
|---|---|---|---|---|---|---|
| Gross Margin | 14.4%-8.0pp | 22.4%-0.8pp | 23.2%-1.4pp | 24.5%-0.6pp | 25.1%-4.7pp | 29.8% |
| Operating Margin | -17.9%-11.8pp | -6.1%-8.8pp | 2.8%-3.9pp | 6.6%-3.1pp | 9.7%-4.4pp | 14.1% |
| Net Margin | -24.6%-13.9pp | -10.7%+12.6pp | -23.4%-58.3pp | 34.9%+33.6pp | 1.3%-7.3pp | 8.6% |
| Return on Equity | -20.6%-13.1pp | -7.5%+7.3pp | -14.8%-30.4pp | 15.6%+14.8pp | 0.9%-7.1pp | 8.0% |
| Return on Assets | -10.3%-6.5pp | -3.7%+4.0pp | -7.8%-17.4pp | 9.6%+9.2pp | 0.4% | N/A |
| Current Ratio | 1.980.0x | 1.94-1.2x | 3.18-0.2x | 3.39+0.2x | 3.16 | N/A |
| Debt-to-Equity | 0.30-0.1x | 0.39+0.1x | 0.280.0x | 0.24-0.2x | 0.46 | N/A |
| Liabilities-to-Equity | 1.010.0x | 1.01+0.1x | 0.90+0.3x | 0.62-0.4x | 1.02 | N/A |
| Asset Turnover | 0.42+0.1x | 0.350.0x | 0.33+0.1x | 0.28-0.1x | 0.34 | N/A |
| FCF Margin | -12.4%+10.2pp | -22.6%-25.9pp | 3.3%+2.0pp | 1.2%+12.1pp | -10.8%-13.3pp | 2.4% |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Evotec SE EVO | FY2024 | $824.9M | -$203.0M | -24.6% | $547.3M | 35/100 |
| Amphastar Pharmaceuticals, Inc. AMPH | FY2025 | $719.9M | $98.1M | 13.6% | $1.1B | 69/100 |
| Tilray Brands, Inc. TLRY | FY2026 | $915.5M | -$121.4M | -13.3% | $433.0M | 41/100 |
| Pacira BioSciences, Inc. PCRX | FY2025 | $726.4M | $7.0M | 1.0% | $1.5B | 52/100 |
| Harrow, Inc. HROW | FY2025 | $272.3M | -$5.1M | -1.9% | $1.1B | 51/100 |
Where Evotec SE Ranks
Frequently Asked Questions
What is Evotec SE's annual revenue?
Evotec SE (EVO) reported $824.9M in total revenue for fiscal year 2024. This represents a -4.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Evotec SE's revenue growing?
Evotec SE (EVO) revenue declined by 4.6% year-over-year, from $864.4M to $824.9M in fiscal year 2024.
Is Evotec SE profitable?
No, Evotec SE (EVO) reported a net loss of $203.0M in fiscal year 2024, with a net profit margin of -24.6%.
What is Evotec SE's EBITDA?
Evotec SE (EVO) had EBITDA of -$42.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Evotec SE have?
As of fiscal year 2024, Evotec SE (EVO) had $317.1M in cash and equivalents against $297.6M in long-term debt.
What is Evotec SE's gross margin?
Evotec SE (EVO) had a gross margin of 14.4% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Evotec SE's operating margin?
Evotec SE (EVO) had an operating margin of -17.9% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Evotec SE's net profit margin?
Evotec SE (EVO) had a net profit margin of -24.6% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Evotec SE's return on equity (ROE)?
Evotec SE (EVO) has a return on equity of -20.6% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Evotec SE's free cash flow?
Evotec SE (EVO) recorded an outflow of $102.7M in free cash flow during fiscal year 2024. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Evotec SE's operating cash flow?
Evotec SE (EVO) generated $18.9M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Evotec SE's total assets?
Evotec SE (EVO) had $2.0B in total assets as of fiscal year 2024, including both current and long-term assets.
What are Evotec SE's capital expenditures?
Evotec SE (EVO) invested $121.6M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Evotec SE spend on research and development?
Evotec SE (EVO) invested $52.6M in research and development during fiscal year 2024.
What is Evotec SE's current ratio?
Evotec SE (EVO) had a current ratio of 1.98 as of fiscal year 2024, which is generally considered healthy.
What is Evotec SE's debt-to-equity ratio?
Evotec SE (EVO) had a debt-to-equity ratio of 0.30 as of fiscal year 2024. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
What is Evotec SE's liabilities-to-equity ratio?
Evotec SE (EVO) had a liabilities-to-equity ratio of 1.01 as of fiscal year 2024, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
What is Evotec SE's return on assets (ROA)?
Evotec SE (EVO) had a return on assets of -10.3% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Evotec SE's P/E ratio?
Evotec SE (EVO) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2024). The market capitalization is $547.3M as of Oct 22, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Evotec SE's price-to-sales ratio?
Evotec SE (EVO) trades at 0.7x sales, its market capitalization divided by $824.9M revenue, FY2024. The market capitalization is $547.3M as of Oct 22, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Evotec SE's Altman Z-Score?
Evotec SE (EVO) has an Altman Z-Score of 0.22, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Evotec SE's Piotroski F-Score?
Evotec SE (EVO) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Evotec SE's earnings high quality?
Evotec SE (EVO) reported a net loss of $203.0M while generating $18.9M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Evotec SE cover its interest payments?
Evotec SE (EVO) reported an operating loss of $147.5M against $4.9M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Evotec SE?
Evotec SE (EVO) scores 35 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.